In contrast to all the other teams, the MC 
team showed a substantially diverse frequency of HLA genes. The proportion of sufferers with HLA-A3 or HLA-A1 alleles was discovered to be lower in lymphoproliferative ailments circumstances than in CHC (19.six% versus 32.8%, p < 0.01). The proportion of HCV-negative individuals with theses alleles was also found to be lower (25.4%). In addition, differences in frequencies were found for the HLA-Bw4 ligand: the proportion of patients with at least one HLA-Bw4 alleles (Bw40I or Bw40T) was higher in MC cases than in NHL cases (76.0% versus 56.4%, p = 0.02). This difference was related to the presence of Bw40I variant. In fact, the frequency of patients with at least one Bw40I allele was higher in MC patients than in NHL (60.0% versus 32.0%, p < 0.01).Known KIR gene-HLA ligand combinations were examined. Statistical difference between KIR-HLA pair frequencies are reported in Table 5. The frequency of KIR3DL1 gene was found to be higher in HCC cases than in CHC (98.3% versus 90.4%, p = 0.01). Furthermore, the proportion of patients having KIR3DL1 with at least one HLA-Bw4 allele (Bw40I or Bw40T) was lower in patients with NHL than in HCC and MC patients (55.4% versus, 69.8% and 75.7%, p = 0.05 and p = 0.01, respectively). Moreover, a significant negative trend was detected for the 3DL1/HLA-B genotype frequencies in NHL patients (from 42.3% for 3DL1/Bw6-Bw6 to 2.6% for both 3DL1/Bw4-I80-Bw4-I80 and 3DL1/Bw4-T80-Bw4-T80 genotypes, CochranArmitage trend test z2 = 1.98, p = 0.047) (Fig. 4).Table 4. Distribution of HLA class I and HLA class I genotype ligands in HCV-negative and in patients with HCV infection and different outcomes. HLA and HLA genotype ligands HCV-- neg No. (%) Chronic HCV No. (%) Hepatocellular carcinoma No. (%) Cryoglobulinemia syndrome No. (%) 118 (100.0) 75 (100.0) HCV patients Lymphoproliferative disorder Non-Hodgkin lymphoma No. (%) 78 (100.0) Total lymphoproliferative diosrders No. (%) 153 (100.0)Fig 4. Distribution of KIR3DL1 gene and combination with HLA-B for patients with different HCV related disease outcomes. It is showed a negative trend association between the KIR3DL1/HLA-Bw4 with the presence of HCV-related lymphoma. 7741044The frequency of EPA ethyl ester manufacturer KIR2DS4 was found to be higher in HCC patients compared to CHC patients (98.3% versus 91.2%, p = 0.02) but independent from the presence of the HLA-Cw04 ligand (Table 5). The frequency of the KIR3DL2 gene combining with either HLA-A03+ or HLA-A11+ ligands was higher in CHC patients than in MC patients (32.8% versus, 14.7% p < 0.01) (Table 5). Activator/Inhibitor KIR genes and HLA matched ligands. Two different patterns of KIR gene and related combinations of HLA ligands werec examinated (Table 6): the inhibitor motif with all of the 2DL3/2DL2/2DL1/3DL1 KIR genes and the activator motif with the 2DS2/ 2DS1/3DS1KIR genes.